[go: up one dir, main page]

MA56187B1 - Traitements de l'angio-oedème héréditaire - Google Patents

Traitements de l'angio-oedème héréditaire

Info

Publication number
MA56187B1
MA56187B1 MA56187A MA56187A MA56187B1 MA 56187 B1 MA56187 B1 MA 56187B1 MA 56187 A MA56187 A MA 56187A MA 56187 A MA56187 A MA 56187A MA 56187 B1 MA56187 B1 MA 56187B1
Authority
MA
Morocco
Prior art keywords
treatments
hereditary angioedema
hae
demand
relates
Prior art date
Application number
MA56187A
Other languages
English (en)
Other versions
MA56187A (fr
Inventor
Edward Paul Feener
Sally Louise Marsh
Andreas Maetzel
Michael David Smith
Christopher Martyn Yea
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of MA56187A publication Critical patent/MA56187A/fr
Publication of MA56187B1 publication Critical patent/MA56187B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des traitements de l'angio-œdème héréditaire (aoh). En particulier, la présente invention concerne des traitements à la demande de l'angio-œdème héréditaire (aoh) par administration orale d'un inhibiteur de kallicréine plasmatique à un patient en ayant besoin, à la demande. Des traitements réguliers (ou continus) de l'aoh sont également proposés.
MA56187A 2019-07-15 2020-06-15 Traitements de l'angio-oedème héréditaire MA56187B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1910116.1A GB201910116D0 (en) 2019-07-15 2019-07-15 Treatments of hereditary angioedema
PCT/GB2020/051439 WO2020249977A1 (fr) 2019-06-14 2020-06-15 Traitements de l'angio-oedème héréditaire

Publications (2)

Publication Number Publication Date
MA56187A MA56187A (fr) 2022-04-20
MA56187B1 true MA56187B1 (fr) 2023-09-27

Family

ID=67700145

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56187A MA56187B1 (fr) 2019-07-15 2020-06-15 Traitements de l'angio-oedème héréditaire

Country Status (34)

Country Link
US (1) US20220218680A1 (fr)
EP (2) EP4282474A3 (fr)
JP (3) JP7356518B2 (fr)
KR (1) KR102748728B1 (fr)
CN (1) CN114126612A (fr)
AR (1) AR119158A1 (fr)
AU (1) AU2020293614B2 (fr)
BR (1) BR112021024664A2 (fr)
CA (1) CA3142218A1 (fr)
CL (2) CL2021003244A1 (fr)
DK (1) DK3982960T3 (fr)
EA (1) EA202193019A1 (fr)
ES (1) ES2956471T3 (fr)
FI (1) FI3982960T3 (fr)
GB (1) GB201910116D0 (fr)
HR (1) HRP20230696T1 (fr)
HU (1) HUE063163T2 (fr)
IL (1) IL288615A (fr)
LT (1) LT3982960T (fr)
MA (1) MA56187B1 (fr)
MD (1) MD3982960T2 (fr)
MX (1) MX2021014557A (fr)
MY (1) MY205687A (fr)
PH (1) PH12021552966A1 (fr)
PL (1) PL3982960T3 (fr)
PT (1) PT3982960T (fr)
RS (1) RS64412B1 (fr)
SG (1) SG11202113304YA (fr)
SI (1) SI3982960T1 (fr)
SM (1) SMT202300261T1 (fr)
TW (1) TW202112370A (fr)
UA (1) UA129869C2 (fr)
WO (1) WO2020249977A1 (fr)
ZA (1) ZA202110685B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
WO2021028645A1 (fr) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
US20230381162A1 (en) * 2020-10-23 2023-11-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
JP2024505596A (ja) * 2021-02-09 2024-02-06 カルビスタ・ファーマシューティカルズ・リミテッド 遺伝性血管性浮腫の治療
HRP20241160T1 (hr) 2022-04-27 2024-11-22 Kalvista Pharmaceuticals Limited Formulacije inhibitora kalikreina u plazmi
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途
WO2025172692A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat à administrer par voie orale pour le traitement d'une attaque d'angioedème héréditaire
WO2025172693A1 (fr) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Sebetralstat oral pour le traitement d'un épisode d'angio-œdème héréditaire
WO2026003532A1 (fr) 2024-06-28 2026-01-02 Kalvista Pharmaceuticals Limited Sébetralstat pour le traitement de l'anxiété associée à un angioedème héréditaire

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CA2658523C (fr) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibiteurs de kallicreine plasmatique
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
WO2012004678A2 (fr) 2010-07-07 2012-01-12 The Medicines Company (Leipzig) Gmbh Inhibiteurs de la sérine protéase
WO2012009009A2 (fr) 2010-07-14 2012-01-19 Addex Pharma S.A. Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
CA2912285C (fr) 2013-05-23 2021-07-13 Kalvista Pharmaceuticals Limited Derives d'amides condenses 6,5 ou 6,6 heteroaromatiques bicycliques et compositions pharmaceutiques de ceux-ci utiles en tant qu'inhibiteurs dela kallicreine plasmatique
EP2815749A1 (fr) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique
EP2886107A1 (fr) * 2013-12-17 2015-06-24 ObsEva S.A. Formules orales de dérivés de pyrrolydine
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema

Also Published As

Publication number Publication date
KR20220024220A (ko) 2022-03-03
AU2020293614A1 (en) 2022-01-27
GB201910116D0 (en) 2019-08-28
HUE063163T2 (hu) 2023-12-28
US20220218680A1 (en) 2022-07-14
PL3982960T3 (pl) 2024-01-15
HRP20230696T1 (hr) 2023-10-13
MD3982960T2 (ro) 2023-12-31
DK3982960T3 (da) 2023-08-21
ES2956471T3 (es) 2023-12-21
KR102748728B1 (ko) 2024-12-30
MA56187A (fr) 2022-04-20
RS64412B1 (sr) 2023-09-29
EP4282474A3 (fr) 2024-02-14
UA129869C2 (uk) 2025-08-27
CL2021003244A1 (es) 2022-09-30
WO2020249977A1 (fr) 2020-12-17
TW202112370A (zh) 2021-04-01
SG11202113304YA (en) 2021-12-30
PT3982960T (pt) 2023-09-26
SI3982960T1 (sl) 2023-10-30
FI3982960T3 (fi) 2023-08-29
JP2022536287A (ja) 2022-08-15
MY205687A (en) 2024-11-06
JP2023166406A (ja) 2023-11-21
BR112021024664A2 (pt) 2022-05-31
CL2023000639A1 (es) 2023-10-30
NZ782935A (en) 2025-02-28
EA202193019A1 (ru) 2022-03-24
CN114126612A (zh) 2022-03-01
AU2020293614B2 (en) 2024-08-15
ZA202110685B (en) 2024-06-26
MX2021014557A (es) 2022-01-11
JP7356518B2 (ja) 2023-10-04
CA3142218A1 (fr) 2020-12-17
JP7688078B2 (ja) 2025-06-03
SMT202300261T1 (it) 2023-09-06
EP3982960B1 (fr) 2023-06-28
EP4282474A2 (fr) 2023-11-29
EP3982960A1 (fr) 2022-04-20
JP2025124716A (ja) 2025-08-26
PH12021552966A1 (en) 2022-07-25
AR119158A1 (es) 2021-12-01
IL288615A (en) 2022-02-01
LT3982960T (lt) 2023-08-25

Similar Documents

Publication Publication Date Title
MA56187B1 (fr) Traitements de l'angio-oedème héréditaire
MY153669A (en) Ocular allergy treatments field of the invention
EP3632444A3 (fr) Antagonistes lfa-1 topiques pour une utilisation dans le traitement localisé de troubles immunitaires associés
WO2004080467A3 (fr) Procede de traitement et de prevention de l'hyperparathyroidie par des composes vitaminiques
WO2006135627A3 (fr) Inhibiteurs de l'activite akt
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
PH12021552967A1 (en) Treatments of angioedema
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
AU2010279892A8 (en) Humanized anti-amyloid-b oligomer antibody
WO2006110638A3 (fr) Inhibiteur de l'activite akt
PH12022550794A1 (en) Oral complement factor d inhibitors
NO20061818L (no) Fremgangsmate for a inhibere remnant lipoproteinproduksjon
EP4245372A3 (fr) Inhibiteur du vhb et son utilisation
SE0200198D0 (sv) New use
WO2004054513A3 (fr) Methodes et compositions de traitement et de prevention d'infections auriculaires
NO20070127L (no) Fremgangsmate for behandling av granuloma annulare eller sarkoid
WO2006068796A3 (fr) Inhibiteurs de l'activite de akt
WO2022063869A3 (fr) Composés pour le traitement d'infections virales
WO2008030260A3 (fr) Traitement des infections virales de la variole au moyen d'un inhibiteur de facteur tissulaire
MX2022004912A (es) Novedoso compuesto de anillo condensado sustituido.
WO2007047205A8 (fr) Inhibiteurs enzymatiques du pai-1
WO2007059356A3 (fr) Inhibiteurs de l'ubiquitine e1
ATE340182T1 (de) Sucroseoctasulphat silber saltz
DK1458376T3 (da) Darifenacin til anvendelse i behandlingen af imperiös vandladningstrang fremkaldt af overaktiv urinblære